AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries - IMI2-2018-15-07

Deadline: May 15, 2019  
CALL EXPIRED

Specific Challenge:

There are significant scientific challenges to the discovery and development of new agents to treat and prevent AMR infections, including those caused by Gram-positive and Gram-negative bacteria, Mycobacterium tuberculosis, and non-tubercular mycobacteria (NTM). Models, approaches, and tools to support antibiotic drug development need to be validated and shared more widely to serve the AMR community. Alternative approaches to treating infections and platforms that enhance the success for vaccines and monoclonal antibodies require robust validation. The AMR Accelerator will provide, under one operational structure, a wide-ranging series of projects that will address many of the scientific challenges in AMR.

Scope:

The Capability Building Network (CBN), Pillar A of the IMI2 AMR Accelerator programme, will work to address the innovation gap in the AMR space by enabling pre-competitive research in the treatment and prevention of multi-drug resistant infections.

The success of the overall Accelerator relies on a coordinated approach to ensure efficient implementation, management, and strategic alignment across a broad range of topics, partners, and stakeholders. The dual aim of this first call for the CBN will be to:

• create an operational group to support the delivery of projects across the Accelerator, specifically: (1) support the project coordinators in horizontal administration of projects, including project and alliance management; (2) centrally source and implement IT infrastructures for projects in the Accelerator; (3) act as an interface with stakeholders in the AMR field to explore synergies and collaboration with other initiatives and contribute to coordinating the broader AMR strategy on a global scale;
• conduct pre-competitive research aimed to (1) provide learnings derived from shared vaccine and/or antibacterial clinical trial data; (2) improve understanding of variability and translatability of animal models of bacterial infection.

Expected Impact:

The expected impact of the CBN will be to: (1) contribute to the development of a vibrant AMR research environment in the EU and strengthening the competitiveness and industrial leadership of Europe; (2) contribute to EU’s ambition of being a ‘best practice region’ for addressing AMR; (3) with other elements of the AMR Accelerator, enhance the overall pipeline of medicines for patients with AMR infections; (4) strengthen interaction of AMR stakeholders from across EU and globally; (5) strengthen the scientific basis on AMR research.